Vaborbactam

Summary

Vaborbactam (CHEMBL3317857) is an approved small molecule; indicated across 3 conditions including urinary tract infection and bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 5
• Chemistry: 297.14 Da · C12H16BNO5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3317857
Name	Vaborbactam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	56649692
Molecular formula	C12H16BNO5S
Molecular weight	297.14
InChIKey	IOOWNWLVCOUUEX-WPRPVWTQSA-N

SMILES: B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O

IUPAC name: 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid

Also known as: RPX-7009, RPX7009, Vaborbactam, Vaborbactam component of carbavance, Vaborbactam component of vabomere, VABORBACTAM

Patent coverage: 194 distinct patent families (442 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	4	MONDO:0100338	EFO:0003103
bacterial infectious disease	1	MONDO:0005113	EFO:0000771
kidney failure	1	MONDO:0001106	HP:0000083

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01751269	PHASE1	COMPLETED	Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects
NCT01772836	PHASE1	COMPLETED	Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination
NCT01897779	PHASE1	COMPLETED	Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects
NCT02020434	PHASE1	COMPLETED	The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency
NCT02073812	PHASE1	COMPLETED	Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).